EPISODE · Sep 13, 2024 · 12 MIN
MPR Weekly Dose Podcast #217 — Novel Ulcerative Colitis Tx; Once-Weekly Insulin Efsitora in T1D; Dupilumab for Urticaria; Ultra-Long Acting Biologic in Asthma; Results for Herpes Vaccine
from MPR Weekly Dose
New drug approved to treat ulcerative colitis; Once-weekly insulin efsitora investigated in type 1 diabetes; Dupilumab shows efficacy for treating urticaria; A twice-yearly injection shows potential for treating severe asthma; and GSK calls an end to their development of a herpes vaccine.
Embed this episode
Ready to play
MPR Weekly Dose Podcast #217 — Novel Ulcerative Colitis Tx; Once-Weekly Insulin Efsitora in T1D; Dupilumab for Urticaria; Ultra-Long Acting Biologic in Asthma; Results for Herpes Vaccine
0:00
12:21
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MPR Weekly Dose?
This episode is 12 minutes long.
When was this MPR Weekly Dose episode published?
This episode was published on September 13, 2024.
Can I download this MPR Weekly Dose episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!